Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 15/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.49 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.48 |
| ▸ | CDK2 | P24941 | 2/20 | 0.48 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.48 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12596657 | 0.89 | GPR119 (0.60) | GPR119CYP3A4CYP2C9CCNA2CDK2 | |
| SCHEMBL304529 | 0.88 | GPR119 (0.55) | GPR119CYP3A4CYP2C9ADORA1 | |
| SCHEMBL10172153 | 0.88 | GPR119 (0.69) | GPR119CYP3A4CYP2C9IRAK4 | |
| SCHEMBL13548263 | 0.88 | GPR119 (0.69) | GPR119CYP3A4CYP2C9IRAK4 | |
| SCHEMBL13971405 | 0.87 | GPR119 (0.76) | GPR119CYP3A4CYP2C9IRAK4 | |
| SCHEMBL10151293 | 0.86 | GPR119 (0.77) | GPR119CYP3A4CYP2C9 | |
| SCHEMBL10137695 | 0.86 | GPR119 (0.57) | GPR119CYP3A4CYP2C9CCNA2CDK2 | |
| SCHEMBL12596381 | 0.85 | GPR119 (0.66) | GPR119CYP3A4CYP2C9CCNA2CDK2 | |
| SCHEMBL11917346 | 0.80 | GPR119 (0.67) | GPR119CYP3A4CYP2C9IRAK4 | |
| SCHEMBL12596514 | 0.79 | GPR119 (0.56) | GPR119CYP3A4CYP2C9IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8476283-B2 | [6,5]—bicyclic GPR119 G protein-coupled receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-02 | — | — | US | disclosed |
| US-20120077826-A1 | [6,5] - BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2012-03-29 | — | — | US | disclosed |
| US-8093257-B2 | [6,5]-bicyclic GPR119 G protein-coupled receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-10 | — | — | US | disclosed |
| US-20090018055-A1 | [6,5]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2009-01-15 | — | — | US | disclosed |
| WO-2008137436-A1 | [6,5]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018055-A1 | [6,5]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | GPR119, GPR139, GPR4 | GPR119 1/4885CYP3A4 1283/4885CYP2C9 767/4885 |
| US-20120077826-A1 | [6,5] - BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | GPR119, GPR139, GPR4 | GPR119 1/4885CYP3A4 1283/4885CYP2C9 767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.